Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Progression-free survival after initial treatment (PFS1) can predict overall survival (OS) in patients with uterine or ovarian carcinosarcomas. A PFS1 threshold may help select patients who benefit from second-line chemotherapy after relapse.
Area Of Science
- Gynecologic Oncology
- Medical Oncology
- Cancer Research
Background
- Uterine and ovarian carcinosarcomas (OCSs) are rare, aggressive cancers.
- Effective treatment strategies, especially after disease progression, remain a challenge.
Purpose Of The Study
- To determine if progression-free survival after initial treatment (PFS1) correlates with the clinical benefit of chemotherapy after disease progression.
- To identify a predictive threshold for PFS1 to guide second-line chemotherapy decisions.
Main Methods
- Retrospective cohort study of 40 patients with uterine or OCS treated between 2010-2022.
- Cox regression and time-dependent ROC curve analysis were used to assess the association between PFS1 and overall survival after progression (OS-PD).
Main Results
- Median PFS1 was 16 months and median OS-PD was 6 months.
- PFS1 significantly predicted OS-PD in patients who relapsed (r=0.61, AUC=0.79).
- A PFS1 threshold of ≤9 months predicted significantly shorter OS-PD (2 months) compared to >9 months (15 months) in patients receiving second-line chemotherapy.
Conclusions
- PFS1 serves as a valuable surrogate for platinum sensitivity in carcinosarcomas.
- PFS1 can aid in selecting patients likely to benefit from second-line chemotherapy after relapse.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
